

cell trafficking pathway used to transport critical proteins, such as transcription factors and cell cycle regulators, into the nucleus. This process is mediated by two intracellular proteins, called karyopherins α & β , that shuttle between the cytoplasm and the nucleus. Many viruses, including HIV-1 and HBV, utilize this established cell trafficking pathway to ensure efficient replication. In most cases, karyopherin α recognizes a set of specific amino acid sequence, called the Nuclear Localization Sequence, located on a viral protein associated with the ribonucleoprotein complex. This association of karyopherin α and the specific viral protein is the pivotal step in nuclear translocation and is the molecular target for NEXT™. Importantly, the present compounds and all future compounds will target the viral component of the protein-protein interaction and not karyopherin α . This approach maximizes specificity of the inhibitory compounds and reduces potential toxicity.

About Presidio Pharmaceuticals, Inc.

Presidio Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on developing and marketing novel therapeutics for chronic virus infections, including HIV-1, CMV, and HCV. Presidio Pharmaceuticals was founded in April 2006 with an initial investment from Sagamore Bioventures, a life-sciences venture fund with headquarters in San Francisco, California, and from George Rathmann.

About Cytokine PharmaSciences, Inc.

Cytokine PharmaSciences is a biopharmaceutical company located in King of Prussia (near Philadelphia), Pennsylvania. The company licenses technologies from academia and other sources, develops products from those technologies and outlicenses the products to third parties for marketing. For more information, go to www.cytokinepharmasciences.com.